{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-025793","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.559288+00:00","generated_at":"2026-06-04T07:37:00.722429+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ABVC enters global licensing deal for Vitargus; potential total fees of $33.5M plus royalties up to $60M","bullets":["20-year exclusive global license with ForSeeCon Eye Corp for ophthalmology pipeline including Vitargus.","ABVC and co-development partner BioFirst each to receive $30M upfront (cash or 5M shares of FEYE at $6/share) within 30 days.","Additional $3.5M cash milestone per party after next fundraise; 5% royalty on net sales capped at $60M per entity.","Vitargus valued at $187M by third-party valuer; ABVC retains R&D role for ophthalmic products.","License covers clinical trial, registration, manufacturing, supply, and distribution rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-025793","json":"https://secwatch.observer/filing/0001213900-24-025793.json","markdown":"https://secwatch.observer/filing/0001213900-24-025793.md","text":"https://secwatch.observer/filing/0001213900-24-025793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024025793/0001213900-24-025793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024025793/ea0202575-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:37:00.722429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}